Short answer
Monopar Therapeutics (MNPR) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 with net income of −$6M.
Q3 2026 key financials · XBRL
- Revenue
- $0
- Net income
- −$6M
- −80.3% YoY · −16.6% QoQ
- EPS (diluted)
- −$0.72
- −50.0% YoY · −16.1% QoQ
Source: XBRL data from the Monopar Therapeutics (MNPR) Q3 2026 10-Q on SEC EDGAR. USD.
Monopar Therapeutics Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no approved drugs or product sales
- Net loss $6.2M vs $3.4M YoY, operating loss $7.5M vs $4.1M
- R&D expense $4.4M vs $2.6M YoY, G&A expense $3.0M vs $1.5M
- Cash, equivalents and investments $129.4M as of September 30, 2026
- Operating cash outflow $12.9M vs $9.1M YoY, funds expected through March 31, 2028; NDA rolling submission completion anticipated within several weeks
Risk Factors
- New regulatory risk: rolling ALXN1840 NDA submission and review, with potential U.S. government shutdown delays
- Most material program change: Alexion terminated ALXN1840 Wilson disease development after Phase 2 review and regulator discussions
- Operational risk: radiopharmaceutical programs depend on adequate radioisotope supply and time-limited product shelf life
- Market risk: larger competitors possess greater capital, organizational, marketing and sales resources
- Financial risk: $104.9 million accumulated deficit, with operations funded through March 31, 2028 by current cash and investments
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Monopar Therapeutics quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.